Novo Nordisk Launches 450-Person Trial to Find Lowest Effective Wegovy Pill Dose — BigGo Finance
Novo Nordisk (NVO) has initiated a late-stage clinical trial to determine whether lower doses of its oral Wegovy…
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)
Key Points Amgen is developing a highly differentiated GLP-1 product. Regeneron has a pair of promising GLP-1 candidates…
Eli Lilly Just Scored Europe’s First Weight Loss Pill Approval — and the Growth Story Keeps Getting Bigger
Key Points Its drug, Foundayo, will compete in Britain against Novo Nordisk’s Wegovy. The global market for GLP-1…
Lilly’s Foundayo Pill Lands First European Approval, Challenging Novo’s Wegovy in UK — BigGo Finance
Eli Lilly and Co. (LLY) has secured its first international approval for the oral weight-loss drug Foundayo, winning…
Novo Nordisk, AWS Form AI Drug Discovery Partnership
Novo Nordisk (NYSE:NVO) and Amazon Web Services have entered a strategic partnership to accelerate drug discovery and modernise…
Novo Nordisk discloses insider restricted share vesting | NVO SEC Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF…
Novo Nordisk updates 2026 share buyback totals | NVO SEC Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF…
Novo Nordisk Buyback Reaches DKK7.78B, 27.9M Shares
Novo Nordisk (NYSE:NVO) provides an update on its share repurchase activity under the Safe Harbour programme initiated on…
Novo Nordisk stock extends pressure as market data stays thin
Novo Nordisk (DK0062498333) stock extends pressure as the available market context stays centered on the companys latest reported…
Novo Nordisk Share Buyback Reaches DKK 7.53B
Novo Nordisk (NYSE:NVO) provides an update on its share repurchase programme conducted under EU Safe…
Novo Nordisk ZEUS Trial: No MACE Benefit, HR 0.99
Novo Nordisk (NYSE:NVO) reported headline results from the phase 3 ZEUS cardiovascular outcomes trial of…
Novo Nordisk drug shows no MACE benefit in ZEUS trial | NVO SEC Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT…